Evidence map›Paper›PMID 42082713›Full record

ArticleNPJ digital medicine2026

Subspecialty-specific foundation model for intelligent gastrointestinal pathology.

Lianghui Zhu, Xitong Ling, Minxi Ouyang, Xiaoping Liu, Tian Guan, Mingxi Fu, Maomao Zeng, Zhiqiang Cheng, Fanglei Fu, Qiang Huang and 10 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lianghui Zhu *Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
Xitong Ling *Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
Minxi Ouyang *Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
Xiaoping Liu *Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Tian GuanInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
Mingxi FuInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
Maomao ZengShenzhen Zhengjingda Instrument Co., Ltd., Shenzhen, China.
Zhiqiang ChengDepartment of Pathology, the Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Fanglei FuInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
Qiang HuangShenzhen Shengqiang Technology Co., Ltd., Shenzhen, China.
Mingxi ZhuInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
Yibo JinSchool of Foreign Studies, Guangzhou University, Guangzhou, China.
Qiming HeInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
Yizhi WangInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
Junru ChengMedical Optical Technology R&D Center, Research Institute of Tsinghua, Guangzhou, China.
Xuanyu WangDepartment of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Luxi XieDepartment of Pathology, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, China. 743361078@qq.com.
Houqiang LiDepartment of Pathology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China. docli254@163.com.
Sufang TianDepartment of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China. sftian@whu.edu.cn.
Yonghong HeInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China. heyh@sz.tsinghua.edu.cn.

Funding

National Natural Science Foundation of China 82430062the Fujian Provincial Natural Science Foundation of China 2024J011006the Jilin FuyuanGuan Food Group Co., Ltd., Fujian Provincial Science and Technology Innovation Joint Funds 2024Y96010076the Shenzhen EngineeringResearch Centre XMHT20230115004
6 · The paper itself

Abstract

Gastrointestinal (GI) diseases pose a major clinical burden, yet conventional histopathology suffers from subjectivity and limited reproducibility. While existing computational pathology foundation models are often validated across many subspecialties in "broad but shallow" benchmarks, they rarely demonstrate deep clinical utility in real-world scenarios. To address this, we develop Digepath-a disease-specialized foundation model focused exclusively on high-impact GI pathology. Our approach employs a two-stage iterative optimization: first, pretraining on over 353 million multi-scale patches from 210,043 H&E-stained slides; second, fine-tuning on 471,443 expert-annotated regions, balancing tumor and non-tumor samples to enhance lesion perception amid sparse pathology in whole-slide images. Digepath achieves state-of-the-art performance on 32 of 33 systematic downstream tasks in GI pathology-including diagnosis, molecular profiling, and survival prognosis-demonstrating robust generalization. Moreover, we integrate its capabilities into an agent-based clinical reasoning framework that supports end-to-end intelligent diagnostic workflows, paving the way for real-world deployment.

Identifiers

PMID42082713
PMCPMC13282484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.